GlassScriptPhysician profile
Bradley D Fox
NPI 1902479843
$5,948.16
in general payments reported to CMS, 2019-2025
46 companies · $1,301 in 2025
The $1,301 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $175 · 2022: $1,372 · 2023: $1,395 · 2024: $1,704 · 2025: $1,301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,392 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,391.59 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,026.04 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,008.88 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Axsome Therapeutics, INC. | $511.44 | 2023-2025 | Auvelity |
| Abbvie INC. | $376.37 | 2021-2023 | |
| Exact Sciences Corporation | $294.29 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $251.23 | 2022-2025 | |
| Glaxosmithkline, LLC. | $205.11 | 2022-2024 | Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $184.57 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $151.70 | 2022-2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $149.69 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $140.73 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $135.29 | 2021-2024 | Spravato |
| Jazz Pharmaceuticals INC. | $125.00 | 2022 | |
| Abbott Laboratories | $124.27 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $122.67 | 2022-2025 | Evenity, Prolia, Otezla |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $117.27 | 2022-2025 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $92.17 | 2023-2025 | Xyosted, Nocdurna, Tlando |
| Biohaven Pharmaceutical Holding Company LTD. | $91.59 | 2022 | |
| Merck Sharp & Dohme LLC | $80.86 | 2021-2025 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.90 | 2024-2025 | Jardiance, Ofev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.40 | 2024-2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $64.04 | 2021-2025 | Zoryve |
| Daiichi Sankyo INC. | $41.28 | 2021-2025 | Injectafer |
| Shield Therapeutics INC | $37.54 | 2023-2025 | Accrufer |
| Takeda Pharmaceuticals U.S.A., INC. | $35.98 | 2022-2025 | Eohilia |
| Sirtex Medical INC | $35.57 | 2024-2025 | Lava Les (Liquid Embolic System) |
| Lundbeck LLC | $34.58 | 2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $29.41 | 2022-2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $29.12 | 2022 | |
| Ani Pharmaceuticals, INC. | $23.62 | 2025 | Purified Cortrophin Gel |
| Pacira Pharmaceuticals Incorporated | $22.45 | 2024 | Zilretta, Iovera, Exparel |
| Tandem Diabetes Care, INC. | $21.84 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $21.25 | 2025 | |
| Agios Pharmaceuticals, INC. | $19.69 | 2025 | Pyrukynd |
| Teva Pharmaceuticals USA, INC. | $19.49 | 2022 | |
| Astellas Pharma US INC | $18.99 | 2023 | Veozah |
| Springworks Therapeutics, INC. | $18.67 | 2025 | Gomekli |
| Alnylam Pharmaceuticals INC. | $18.52 | 2023 | Onpattro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.82 | 2025 | Caplyta |
| Phadia US INC. | $17.38 | 2024 | Immunocap |
| Amarin Pharma, INC. | $17.01 | 2022 | |
| Radius Health, INC. | $15.33 | 2024 | Tymlos |
| Currax Pharmaceuticals LLC | $15.00 | 2024 | Contrave |
| Bausch Health US, LLC | $14.36 | 2022 | |
| Dynavax Technologies Corporation | $13.52 | 2024 | Heplisav-B |
| Rhythm Pharmaceuticals, INC. | $13.23 | 2024 | Imcivree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.